Qiagen N.V. (QGEN) 23.68 $QGEN
Largest-Ever Pivotal Study in China Supports QIAGEN's QuantiFERON®-TB Gold Over Tuberculin Skin Test for Latent Tuberculosis Infection
PR Newswire - Wed Feb 11, 9:24AM CST
-- China's first population-based study of latent TB infection, published in The Lancet, recommends screening and preventive treatment for vulnerable patients
QGEN: 23.68 (-0.06)
Update: Qiagen Posted Disappointing Q4 2014 Earnings
Andy Batts - at Seeking Alpha - Fri Feb 06, 5:40PM CST
QGEN: 23.68 (-0.06)
Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4g8s4/molecular) has announced the addition of the "Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics" report to their offering. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - Siemens AG - SIRS-Lab - TrovaGene - Veredus Laboratories - Veridex, LLC (Janssen Diagnostics, LLC) For more information visit http://www.researchandmarkets.com/research/b4g8s4/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Qiagen (QGEN) Disappoints with Q4 Earnings, Revenue Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 1:20PM CST
Qiagen NV (QGEN), a provider of sample and assay technologies, posted a disappointing fourth-quarter 2014 with lower-than-expected earnings and revenues.
ACAD: 34.21 (+0.37), ALXN: 182.29 (+6.02), QGEN: 23.68 (-0.06), AFFX: 11.45 (+0.02)
Qiagen NV (QGEN) Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 29, 1:00PM CST
QGEN: 23.68 (-0.06)
Qiagen NV Looks To the Future
Todd Campbell, The Motley Fool - Motley Fool - Thu Jan 29, 11:19AM CST
Source: Qiagen NV Qiagen NV solutions are used every day by healthcare providers to analyze patient DNA and RNA in order to guide treatment and by researchers pursuing next generation medicine. The opportunity for Qiagen to help the industry...
QGEN: 23.68 (-0.06)
Qiagen updates guidance after Q4 results
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 10:32AM CST
QGEN: 23.68 (-0.06)
Qiagen misses Street 4Q forecasts
Automated Insights - Wed Jan 28, 4:27PM CST
VENLO, Netherlands (AP) _ Qiagen NV (QGEN) on Wednesday reported fourth-quarter profit of $25.8 million.
QGEN: 23.68 (-0.06)
Qiagen misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 3:01PM CST
QGEN: 23.68 (-0.06)
QIAGEN Reports Results for Fourth Quarter and Full-Year 2014
PR Newswire - Wed Jan 28, 3:00PM CST
-- Full-year 2014 results: Adjusted net sales of $1.35 billion (+4% CER); adjusted operating income of $312.5 million; and adjusted EPS of $1.00 - Adjusted net sales rise 9% CER excluding U.S. HPV products; free cash flow up 15% to $201.4 million for the year
QGEN: 23.68 (-0.06)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 4:35PM CST
GHL: 38.24 (+1.20), SLG: 128.59 (-0.65), AMP: 137.81 (+0.24), CTXS: 64.51 (+0.80), NOW: 77.55 (+1.60), MKSI: 35.56 (-0.25), EXTR: 3.46 (+0.10), CAVM: 62.86 (-0.55), VRTX: 113.66 (+4.03), ESIO: 6.50 (+0.02), JEC: 43.27 (+0.71), TTEK: 24.58 (+0.08), FB: 75.74 (-0.49), PTC: 34.02 (+0.37), CLB: 112.18 (+3.65), UMPQ: 16.82 (+0.17), IEX: 77.14 (+0.77), VAR: 92.65 (+0.03), AVB: 170.82 (-2.57), AZPN: 38.40 (+0.79), AF: 13.18 (+0.04), CGI: 25.30 (+0.05), SHOR: 7.48 (-0.03), FLEX: 12.05 (-0.09), CSII: 35.69 (+0.17), CPT: 75.24 (-1.03), KEX: 79.37 (+1.28), LVS: 60.43 (+1.71), TSCO: 84.26 (+0.99), STLD: 20.01 (+0.19), DHT: 6.99 (+0.05), MUR: 51.77 (+0.88), SWFT: 26.96 (+0.53), ALB: 54.59 (+0.63), IBKC: 63.08 (+0.45), QCOM: 70.88 (+0.49), CACI: 88.00 (+0.42), QGEN: 23.68 (-0.06), TER: 19.43 (+0.04), MEOH: 53.17 (+2.19), DRE: 21.63 (+0.04), SGI: 9.59 (+0.17), TGI: 61.33 (+1.18), CMO: 11.84 (+0.02), ATK: 140.03 (+0.78), ISIL: 15.30 (-0.25), ALGT: 178.42 (-4.07), GGP: 29.25 (-0.28), PRXL: 62.91 (-0.18), LRCX: 82.21 (+1.10), CRUS: 29.36 (+0.01), MLNX: 46.35 (+1.47), FTNT: 33.23 (+0.25), CBT: 47.04 (-0.10), HOLX: 30.46 (+0.21)
QIAGEN Introduces QuantiFERON Monitor® for Tracking Immune Function in Solid Organ Transplant Patients and for Research Into Other Applications
PR Newswire - Tue Jan 27, 3:00PM CST
-- QuantiFERON Monitor (QFM®) launches in Europe for monitoring immune function
QGEN: 23.68 (-0.06)
Interesting QGEN Call Options For March 20th
DividendChannel.com - Mon Jan 26, 10:37AM CST
Investors in Qiagen N. .
QGEN: 23.68 (-0.06)
Qiagen reports January 28
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 8:23AM CST
QGEN: 23.68 (-0.06)
QIAGEN N.V. to Report Fourth Quarter and Full-Year 2014 Results
PR Newswire - Fri Jan 16, 6:42AM CST
QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans to release its report on results for the fourth quarter and full year 2014 on Wednesday, January 28, at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). Also as previously announced, a conference call is planned for Thursday, January 29, at 15:30 CET / 9:30 ET that will include remarks by Peer M. Schatz, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
QGEN: 23.68 (-0.06)
Qiagen Up on CE-IVD Mark for New Liquid Biopsy Test Kit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 1:10PM CST
Qiagen (QGEN) currently offers the therascreen EGFR test as a tissue-based companion diagnostic for lung cancer patients in the U.S. and China.
AZN: 69.96 (+0.20), ALXN: 182.29 (+6.02), QGEN: 23.68 (-0.06), AFFX: 11.45 (+0.02)
Qiagen Up on Enzymatics' Unit Buy, ArcherDX Partnership Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 1:30PM CST
Qiagen (QGEN) expects this buyout to provide approximately $20 million CER (constant exchange rates) of incremental net sales
ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), QGEN: 23.68 (-0.06), AFFX: 11.45 (+0.02)
Will Qiagen's Qiasymphony Placements Weave Magic in 2015? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 1:30PM CST
Qiagen's (QGEN) QIAsymphony automation solution refers to a revolutionizing molecular testing workflow which offers flexible and effective processing from sample to valuable clinical insight,
ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), QGEN: 23.68 (-0.06), AFFX: 11.45 (+0.02)
Qiagen (QGEN) Launches Next-Gen TB Infection Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 1:40PM CST
Qiagen's (QGEN) QFT-Plus is the fourth generation of the most accurate test used in the diagnosis of tuberculosis (TB) infection.
ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), QGEN: 23.68 (-0.06), AFFX: 11.45 (+0.02)
ArcherDX Launches from QIAGEN Acquisition of Enzymatics
Business Wire - Mon Jan 12, 10:14AM CST
-- Jason Myers, Ph.D., becomes Chief Executive Officer of ArcherDX --
QGEN: 23.68 (-0.06)
Largest-Ever Pivotal Study in China Supports QIAGEN's QuantiFERON®-TB Gold Over Tuberculin Skin Test for Latent Tuberculosis Infection
PR Newswire - Wed Feb 11, 9:24AM CST
-- China's first population-based study of latent TB infection, published in The Lancet, recommends screening and preventive treatment for vulnerable patients
QGEN: 23.68 (-0.06)
Update: Qiagen Posted Disappointing Q4 2014 Earnings
Andy Batts - at Seeking Alpha - Fri Feb 06, 5:40PM CST
QGEN: 23.68 (-0.06)
Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/b4g8s4/molecular) has announced the addition of the "Global Molecular Diagnostics in Infectious Disease Testing Overview Report: Infectious disease space is the most dominant and profitable sector of molecular diagnostics" report to their offering. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts. This publications report describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics-along with the development of microarray devices to measure analytes in the blood-has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics for Infectious Disease Testing 3. Infectious Disease Diagnostics Molecular Testing Market 4. Molecular Diagnostic Testing Technology for Infectious Disease Testing 5. Business 6. Reimbursement and Billing Landscape for Molecular Diagnostics Testing for Infectious Disease 7. Regulatory Requirements 8. Business Decisions using Molecular Diagnostic Tests in Infectious Disease Testing 9. Economics of Anti-Microbial Drug Resistance: The Persistent Need for Antibacterials 10. Company Profiles - Abbott Laboratories - AdvanDx - Affymetrix - Arcxis Biotechnologies - Asuragen, Inc. - AutoGenomics, Inc. - Becton, Dickinson and Company - bioM?rieux - bioTheranostics - Cepheid - EraGen Biosciences - GenMark Diagnostics, Inc. - Genomix Biotech - Gen-Probe, Inc. (now known as Hologic Gen-Probe) - Genomica S.A.U. - Illumina, Inc. - Life Technologies (Thermo Fisher Scientific) - Luminex Corp. - Mobidiag - Myconostica - Myriad Genetics, Inc. - Nanosphere - NorDiag ASA (The DiaSorin Group) - Qiagen N.V. - Quidel - Roche Diagnostics (Roche Ltd.) - Siemens AG - SIRS-Lab - TrovaGene - Veredus Laboratories - Veridex, LLC (Janssen Diagnostics, LLC) For more information visit http://www.researchandmarkets.com/research/b4g8s4/molecular
GNMK: 13.51 (+0.21), ABT: 46.09 (+0.87), MYGN: 34.03 (+0.40), AGMX: (), CPHD: 59.62 (+0.72), ILMN: 198.54 (+1.81), QGEN: 23.68 (-0.06), LMNX: 15.45 (+0.02)
Qiagen (QGEN) Disappoints with Q4 Earnings, Revenue Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 1:20PM CST
Qiagen NV (QGEN), a provider of sample and assay technologies, posted a disappointing fourth-quarter 2014 with lower-than-expected earnings and revenues.
ACAD: 34.21 (+0.37), ALXN: 182.29 (+6.02), QGEN: 23.68 (-0.06), AFFX: 11.45 (+0.02)
Qiagen NV (QGEN) Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 29, 1:00PM CST
QGEN: 23.68 (-0.06)
Qiagen NV Looks To the Future
Todd Campbell, The Motley Fool - Motley Fool - Thu Jan 29, 11:19AM CST
Source: Qiagen NV Qiagen NV solutions are used every day by healthcare providers to analyze patient DNA and RNA in order to guide treatment and by researchers pursuing next generation medicine. The opportunity for Qiagen to help the industry...
QGEN: 23.68 (-0.06)
Qiagen updates guidance after Q4 results
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 10:32AM CST
QGEN: 23.68 (-0.06)
Qiagen misses Street 4Q forecasts
Automated Insights - Wed Jan 28, 4:27PM CST
VENLO, Netherlands (AP) _ Qiagen NV (QGEN) on Wednesday reported fourth-quarter profit of $25.8 million.
QGEN: 23.68 (-0.06)
Qiagen misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 3:01PM CST
QGEN: 23.68 (-0.06)
QIAGEN Reports Results for Fourth Quarter and Full-Year 2014
PR Newswire - Wed Jan 28, 3:00PM CST
-- Full-year 2014 results: Adjusted net sales of $1.35 billion (+4% CER); adjusted operating income of $312.5 million; and adjusted EPS of $1.00 - Adjusted net sales rise 9% CER excluding U.S. HPV products; free cash flow up 15% to $201.4 million for the year
QGEN: 23.68 (-0.06)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 4:35PM CST
GHL: 38.24 (+1.20), SLG: 128.59 (-0.65), AMP: 137.81 (+0.24), CTXS: 64.51 (+0.80), NOW: 77.55 (+1.60), MKSI: 35.56 (-0.25), EXTR: 3.46 (+0.10), CAVM: 62.86 (-0.55), VRTX: 113.66 (+4.03), ESIO: 6.50 (+0.02), JEC: 43.27 (+0.71), TTEK: 24.58 (+0.08), FB: 75.74 (-0.49), PTC: 34.02 (+0.37), CLB: 112.18 (+3.65), UMPQ: 16.82 (+0.17), IEX: 77.14 (+0.77), VAR: 92.65 (+0.03), AVB: 170.82 (-2.57), AZPN: 38.40 (+0.79), AF: 13.18 (+0.04), CGI: 25.30 (+0.05), SHOR: 7.48 (-0.03), FLEX: 12.05 (-0.09), CSII: 35.69 (+0.17), CPT: 75.24 (-1.03), KEX: 79.37 (+1.28), LVS: 60.43 (+1.71), TSCO: 84.26 (+0.99), STLD: 20.01 (+0.19), DHT: 6.99 (+0.05), MUR: 51.77 (+0.88), SWFT: 26.96 (+0.53), ALB: 54.59 (+0.63), IBKC: 63.08 (+0.45), QCOM: 70.88 (+0.49), CACI: 88.00 (+0.42), QGEN: 23.68 (-0.06), TER: 19.43 (+0.04), MEOH: 53.17 (+2.19), DRE: 21.63 (+0.04), SGI: 9.59 (+0.17), TGI: 61.33 (+1.18), CMO: 11.84 (+0.02), ATK: 140.03 (+0.78), ISIL: 15.30 (-0.25), ALGT: 178.42 (-4.07), GGP: 29.25 (-0.28), PRXL: 62.91 (-0.18), LRCX: 82.21 (+1.10), CRUS: 29.36 (+0.01), MLNX: 46.35 (+1.47), FTNT: 33.23 (+0.25), CBT: 47.04 (-0.10), HOLX: 30.46 (+0.21)
QIAGEN Introduces QuantiFERON Monitor® for Tracking Immune Function in Solid Organ Transplant Patients and for Research Into Other Applications
PR Newswire - Tue Jan 27, 3:00PM CST
-- QuantiFERON Monitor (QFM®) launches in Europe for monitoring immune function
QGEN: 23.68 (-0.06)
Interesting QGEN Call Options For March 20th
DividendChannel.com - Mon Jan 26, 10:37AM CST
Investors in Qiagen N. .
QGEN: 23.68 (-0.06)
Qiagen reports January 28
Seeking Alpha - at Seeking Alpha - Fri Jan 16, 8:23AM CST
QGEN: 23.68 (-0.06)
QIAGEN N.V. to Report Fourth Quarter and Full-Year 2014 Results
PR Newswire - Fri Jan 16, 6:42AM CST
QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans to release its report on results for the fourth quarter and full year 2014 on Wednesday, January 28, at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). Also as previously announced, a conference call is planned for Thursday, January 29, at 15:30 CET / 9:30 ET that will include remarks by Peer M. Schatz, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
QGEN: 23.68 (-0.06)
Qiagen Up on CE-IVD Mark for New Liquid Biopsy Test Kit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 1:10PM CST
Qiagen (QGEN) currently offers the therascreen EGFR test as a tissue-based companion diagnostic for lung cancer patients in the U.S. and China.
AZN: 69.96 (+0.20), ALXN: 182.29 (+6.02), QGEN: 23.68 (-0.06), AFFX: 11.45 (+0.02)
Qiagen Up on Enzymatics' Unit Buy, ArcherDX Partnership Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 1:30PM CST
Qiagen (QGEN) expects this buyout to provide approximately $20 million CER (constant exchange rates) of incremental net sales
ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), QGEN: 23.68 (-0.06), AFFX: 11.45 (+0.02)
Will Qiagen's Qiasymphony Placements Weave Magic in 2015? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 1:30PM CST
Qiagen's (QGEN) QIAsymphony automation solution refers to a revolutionizing molecular testing workflow which offers flexible and effective processing from sample to valuable clinical insight,
ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), QGEN: 23.68 (-0.06), AFFX: 11.45 (+0.02)
Qiagen (QGEN) Launches Next-Gen TB Infection Test - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 1:40PM CST
Qiagen's (QGEN) QFT-Plus is the fourth generation of the most accurate test used in the diagnosis of tuberculosis (TB) infection.
ALXN: 182.29 (+6.02), AMAG: 41.49 (+0.23), QGEN: 23.68 (-0.06), AFFX: 11.45 (+0.02)
ArcherDX Launches from QIAGEN Acquisition of Enzymatics
Business Wire - Mon Jan 12, 10:14AM CST
-- Jason Myers, Ph.D., becomes Chief Executive Officer of ArcherDX --
QGEN: 23.68 (-0.06)
